Related Experiment Videos
Abciximab in ST-elevation acute myocardial infarction occurring in a heart transplant recipient and treated with
Leonardo Varotto1, Luigi La Vecchia, Alessandro Fontanelli
1Division of Cardiology, Catheterization Laboratory, Vicenza, Italy.
Insights
This study reports successful direct stenting with abciximab for acute myocardial infarction in a heart transplant patient. The procedure maintained coronary artery patency for one year, showing promise for allograft coronary artery disease.
Area of Science:
- Cardiology
- Transplantation Medicine
- Interventional Cardiology
Background:
- Heart transplant recipients can develop allograft coronary artery disease.
- Acute myocardial infarction is a critical complication in these patients.
- Current treatment guidelines for myocardial infarction may not fully address transplant recipients.
Observation:
- A heart transplant recipient with triple-vessel disease presented with acute anterior myocardial infarction.
- Direct stenting was performed after abciximab administration.
- The procedure achieved primary success.
Findings:
- The patient survived to a one-year angiographic follow-up.
- Coronary patency was persistently maintained.
- This represents the first report of abciximab use in primary stenting for myocardial infarction in allograft coronary artery disease.
Implications:
- Abciximab may be a viable option for primary stenting in acute myocardial infarction within allograft coronary artery disease.
- This case highlights the importance of tailored interventional strategies in transplant recipients.
- Further research is warranted to evaluate the efficacy and safety of abciximab in this specific patient population.
Abstract:
The authors describe primary coronary intervention consisting of direct stenting after abciximab administration in a case of acute anterior myocardial infarction occurring in a heart transplant recipient with triple-vessel disease. Primary success was obtained and the patient survived to a one-year angiographic follow up which showed persistent coronary patency. This is the first report concerning the use of abciximab in primary stenting for acute myocardial infarction in allograft coronary artery disease.
